ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2697

Identification Of Genetic and Epigenetic Alterations In Spondyloarthritis

Tibor A. Rauch1, Beata Tryniszewska1, Andras Vida1, Timea Ocsko1, Sandor Szanto2, Holly L. Rosenzweig3, Matthew A. Brown4, Gethin P Thomas5, Katalin Mikecz1 and Tibor T. Glant1, 1Orthopedic Surgery, Rush University Medical Center, Chicago, IL, 2Rheumatology, University of Debrecen, Debrecen, Hungary, 3Oregon Health & Science University, Portland, OR, 4Translational Research Institute, University of Queensland Diamantina Institute, Brisbane, Australia, 5Translational Reserch Institute, University of Queensland Diamantina Institute, Woolloongabba, Australia

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Ankylosing spondylitis (AS), Epigenetics, genetics, spondylarthritis and spondylarthropathy

  • Tweet
  • Email
  • Print
Session Information

Title: Spondylarthropathies and Psoriatic Arthritis - Pathogenesis, Etiology

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Ankylosing spondylitis (AS) is the prototypic spondyloarthritis and affects approximately 0.2-0.5% of the human population. It is estimated that genetic risk factors contribute >90% of disease susceptibility, and the major genetic risk factor is HLA-B27. Approximately the other half of the genetic risk is composed by non-MHC traits. By generating interval-specific congenic (IVSC) strains utilizing the genetic combination of proteoglycan-induced SpA (PGISpA) in susceptible BALB/c mice and SpA-resistant DBA/2 mice (both carry the same MHC) we can identify non-MHC causative genes by excluding the effect of the MHC. These IVSC strains with overlapping chromosome (Chr) regions were used to narrow the (Pgis2) risk locus on mouse Chr2 (mChr2) to a small region syntenic with AS risk loci on human chromosomes 4 and 9.

Methods:

PGISpA-resistant DBA/2 and –susceptible BALB/c strains were intercrossed, and then backcrossed with BALB/c mice until the entire Pgis2 locus (mChr2) was from DBA/2 on a full BALB/c background. Congenic mice were tested for PGISpA, and then backcrossed to BALB/c strain. Recombination events were genotyped until partially overlapping DBA/2 intervals (n=12) completely covered the Pgis2 locus. Heterozygous females and males with the same genomic intervals were intercrossed, homozygous offspring tested for PGISpA. Based on the overlapping Chr2 intervals, we narrowed a resistant (DBA/2 origin) to ~3.5 Mbp in size (mChr2:30.5-34.0 Mbp; syntenic with hChr9:129.-132.8 Mbp). All IVSC mice were tested with near infrared OsteoSenseTM 750 (Visen Medical) probe, spine histology, serum cytokines and cytokines in antigen-stimulated in vitro spleen cell cultures. The corresponding 3 Mbp genomic regions of PGISpA-resistant and –susceptible IVSC and parent strains (n=10) were sequenced by high-throughput methods and analyzed using the GeneSpring NGS program.

Results:

We identified a total of 4,416 mutations within the 3.5 Mbp-long genomic region . The 3.5 Mbp region contains 70 protein-coding genes, 12 antisense transcripts (RNA) and 25 different forms (small nucloelar, miRNA) of non-coding RNAs. Mutations/indels were detected (93.38%) in three relatively small genomic regions affecting 3 (Gpr107-Nsc1-Hmcn2) genes and their intergenic regions, and two other genes (St6galnac6 and Lmx1b). PGISpA was significantly reduced (p<0.001) in each IVSC strain carrying any of these three DBA/2 alleles. The Gpr107-Nsc1-Hmcn2 triplet contained mutations affecting multiple transcription binding sites, the Lmx1b transcription factor has an in-frame 18-nucleotide deletion in exon 1, and the promoter region of the St6galnac6 was hypermethylated in genomic regions of DBA/2 origin.

Conclusion:

Although all three alleles affected PGISpA individually, it appears that an “epistatic triangle” exists among these alleles that protect against PGISpA. Overall, all mutations with predicted functional consequence are located in non-coding sequences underlining the critical role of epigenetic alterations in PGISpA (and perhaps in AS).


Disclosure:

T. A. Rauch,
None;

B. Tryniszewska,
None;

A. Vida,
None;

T. Ocsko,
None;

S. Szanto,
None;

H. L. Rosenzweig,
None;

M. A. Brown,
None;

G. P. Thomas,
None;

K. Mikecz,
None;

T. T. Glant,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/identification-of-genetic-and-epigenetic-alterations-in-spondyloarthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology